NMTC Stock Analysis: Buy, Sell, or Hold?
NMTC - NeuroOne Medical Technologies Corporation Common Stock
$2.14
0.11 (5.42%)
▲
5d:
+13.83%
30d:
+12.63%
90d:
-42.01%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When NMTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NMTC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NMTC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NMTC is currently trading at $2.14, which is considered extended relative to its 30-day fair value range of $1.62 to $2.06.
Technical Outlook: Technically, NMTC is in a downtrend. Immediate support is located at $1.46, while resistance sits at $2.37. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: NMTC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.27 (+239.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NMTC is in a downtrend. Immediate support is located at $1.46, while resistance sits at $2.37. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: NMTC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.27 (+239.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.62 -
$2.06
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 239.6% below Wall St target ($7.27)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.62 -
$2.06
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.46
Resistance Level
$2.37
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.38
Wall Street Target
$7.27
(+239.6%)
Revenue Growth (YoY)
16.3%
Profit Margin
-59.7%
Share & Embed Analysis
Last updated: August 25, 2026 6:31 AM ET
Data refreshes hourly during market hours. Next update: 7:31 AM
Data refreshes hourly during market hours. Next update: 7:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMTC showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Christianson
SELL
16 shares
2026-03-13
Mark Christianson
SELL
136 shares
2026-03-12
Mark Christianson
SELL
351 shares
2026-03-11
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 46 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 60 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 33 SELL |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 44 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 54 HOLD |
